eigerbioadmin

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs PALO ALTO, Calif., June 10, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, today announced the appointment of Mark Mannebach, PhD, RPh as Vice President [...]

Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer PALO ALTO, Calif., May 17, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Apelian will step down as the Company’s Chief Operating Officer and Executive Medical [...]

Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update First-Ever Phase 3 HDV International “D-LIVR” Study UnderwayNDA and MAA filings for Progeria & Progeroid Laminopathies planned in 2019Strong Balance Sheet with Recent Financing CompletedPALO ALTO, Calif., May 9, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted [...]

Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors PALO ALTO, Calif., April 15, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Amit K. Sachdev, JD to its Board [...]